Ken Griffin Procept Bio Robotics Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$56.31 - $84.99 $540,576 - $815,904	-9,600 Reduced 26.37%	26,800 $2.15 Million
Q2 2024 Aug 14, 2024	SELL	$45.73 - $69.19 $768,264 - $1.16 Million	-16,800 Reduced 31.58%	36,400 $2.22 Million
Q1 2024 May 15, 2024	SELL	$40.38 - $50.75 $177,672 - $223,300	-4,400 Reduced 7.64%	53,200 $2.63 Million
Q4 2023 Feb 14, 2024	BUY	$24.89 - $43.41 $973,199 - $1.7 Million	39,100 Added 211.35%	57,600 $2.41 Million
Q3 2023 Nov 14, 2023	SELL	$30.02 - $38.81 $1.46 Million - $1.89 Million	-48,800 Reduced 72.51%	18,500 $606,000
Q2 2023 Aug 14, 2023	BUY	$26.7 - $37.02 $58,740 - $81,444	2,200 Added 3.38%	67,300 $2.38 Million
Q1 2023 May 15, 2023	BUY	$26.64 - $39.74 $1.41 Million - $2.11 Million	53,100 Added 442.5%	65,100 $1.85 Million
Q4 2022 Feb 14, 2023	SELL	$38.78 - $46.78 $54,292 - $65,492	-1,400 Reduced 10.45%	12,000 $498,000
Q3 2022 Nov 14, 2022	BUY	$30.9 - $50.65 $414,060 - $678,710	13,400 New	13,400 $556,000

266

38M

262K

257K

Ticker PRCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 44,592,300
Market Cap $3.73B
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.